GlassScriptPhysician profile
Young Ho Lee
NPI 1922101500
$3,498.62
in general payments reported to CMS, 2019-2025
34 companies · $579 in 2025
The $579 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $168 · 2021: $508 · 2022: $605 · 2023: $548 · 2024: $528 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,654.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $701.42 | 2019-2023 | Xarelto, Spravato |
| Abbvie INC. | $445.10 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $346.73 | 2024-2025 | Voquezna |
| Amgen INC. | $245.39 | 2019-2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $195.98 | 2019-2024 | Farxiga, Breztri |
| Lilly USA, LLC | $181.46 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Gilead Sciences, INC. | $169.92 | 2021-2023 | |
| Braemar Manufacturing, LLC | $157.92 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.87 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.57 | 2019-2024 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $69.70 | 2020-2024 | Arexvy, Trelegy Ellipta |
| Shield Therapeutics INC | $69.53 | 2023 | Accrufer |
| Amarin Pharma, INC. | $62.92 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $62.54 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $61.07 | 2023-2025 | Gemtesa |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $58.63 | 2020-2024 | |
| Novo Nordisk INC | $46.66 | 2019-2025 | Wegovy |
| Astellas Pharma US INC | $44.18 | 2023-2024 | Veozah |
| Ibsa Pharma INC. | $41.37 | 2024 | Licart, Tirosint, Flector |
| Biogen, INC. | $41.04 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $39.37 | 2022 | |
| Fidia Pharma USA INC. | $34.20 | 2019-2025 | Hyalgan |
| Pfizer INC. | $29.76 | 2023 | |
| Xeris Pharmaceuticals, INC. | $24.75 | 2024 | Gvoke Hypopen |
| Abbott Laboratories | $24.22 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $23.08 | 2025 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $23.08 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $21.44 | 2019 | |
| Corium, LLC | $21.07 | 2022 | |
| Sunovion Pharmaceuticals INC. | $20.47 | 2021 | |
| Ascensia Diabetes Care US INC. | $18.77 | 2024 | |
| Esperion Therapeutics, INC. | $18.64 | 2022 | |
| Mylan Specialty L.P. | $16.04 | 2024 | Yupelri |
| Acadia Pharmaceuticals INC | $15.73 | 2023 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Young Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.